BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diao Q, Guo H, Wang G. Benzofuran–isatin Hybrids: Design, Synthesis, and In Vitro Anti‐cancer Activities. J Heterocyclic Chem 2019;56:1687-93. [DOI: 10.1002/jhet.3554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zou Y. Benzofuran‐isatin conjugates as potent VEGFR‐2 and cancer cell growth inhibitors. J Heterocyclic Chem 2019;57:510-6. [DOI: 10.1002/jhet.3795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Ding Z, Zhou M, Zeng C. Recent advances in isatin hybrids as potential anticancer agents. Arch Pharm (Weinheim) 2020;353:e1900367. [PMID: 31960987 DOI: 10.1002/ardp.201900367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
3 Jia Y, Wen X, Gong Y, Wang X. Current scenario of indole derivatives with potential anti-drug-resistant cancer activity. Eur J Med Chem 2020;200:112359. [PMID: 32531682 DOI: 10.1016/j.ejmech.2020.112359] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
4 Guo H, Diao QP. The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds. Curr Top Med Chem 2020;20:1499-503. [PMID: 32156238 DOI: 10.2174/1568026620666200310124416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]